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FOREWORD 
The first series of reports of the Scientific Committee for Animal 
Nutrition was published in 1979 (1). This collection constitutes the 
second series and contains the Committee's opinions on the use of 
certain additives in feedingstu-ffs together with a chapter entitled 
"Guidelines for the Assessment of Additives in Feedingstuffs". 
The opinions of the Committee relate to questions put to it by the 
Commission on the safety of certain additives used to promote growth 
in chickens, pigs and cattle for fattening, or to prevent coccidiosis 
in chickens. Since consideration was being given to authorization 
of these additives at Community Level, it was important to ensure, 
on the basis of sound scientific advice, that they are safe to use 
under the conditions proposed. 
The Commission also felt it would be useful to publish the guidelines, 
which had been approved by the Committee, on the contents of the 
dossiers required to assess substances for authorization as feeding-
stuffs additives. These guidelines, which are published in response 
to frequent requests for information, should help to achieve a more 
uniform implementation of Community provisions governing the authori-
zation of feedingstuffs additives. 
(1) Office for Official Publications of the European Communities, 
Luxembourg. No: CB-28-79-277-EN-C 
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REPORT OF THE SCIENTIFIC COMMITTEE FOR ANIMAL NUTRITION ON 
THE USE OF CARBADOX IN FEEDINGSTUFFS FOR PIGS 
Opinion expressed 6 July 1978 
TERMS OF REFERENCE 
The Scientific Committee for Animal Nutrition was requested to give 
an opinion on the following questions : 
1. Does the use of the growth promotor carbadox in feedingstuffs for 
pigs, under the conditions of use authorized by derogation (see 
Background), result in the presence of residues in animal products ? 
If so, what is the nature and the amount of these residues ? 
Could these residues be harmful to the consumer ? 
2. Could the use of this additive affect the development of resistance 
in bacteria ? 
3. Could this use be prejudicial to persons required to handle this 
product in industry and/or agriculture or to the environment ? 
If so, what is the nature of the risks ? 
4. In the light of the answers to the above questions, should the 
conditions of use already authorized for this additive be main-
tained or should they be modified ? 
BACKGROUND 
In accordance with the provisions of Council Directive 70/524/EEC, of 
23 November 1970, concerning additives in feedingstuffs (1), as last 
amended by the twenty-third Commission Directive of 23 June 1978 (2), 
Member States are authorized to use carbadox, by way of derogation 
up to 31 December 1978, under the following conditions set out in 
Annex II, Section F, of the Directive : 
Species of animal : pigs, up to four months. 
Maximum content in complete feedingstuffs : 50 ppm (mg/kg). 
Other provisions : use prohibited for at least 4 weeks before slaughter. 
Mixing or simultaneous administration with an antibiotic prohibited. 
(1) 0J No L 270, 14.12.1970, p. 1 
(2) 0J No L 198, 22.07.1978, p. 10 
­ 8 
OPINION OF THE COMMITTEE 
Carbadox (methyl­3­(2­quinoxalinyI methylene)­carbazate­Ν,Ν'­dioxide) 
is metabolized in pigs to quinoxaline­2­carboxylic acid and methyl­
carbazate with the intermediary formation of desoxycarbadox 
(methyl­3­(2­quinoxaLine­methyLene) carbazate). Carbadox and 
desoxycarbadox have a short Life­time. After three weeks admini­
stration of 3.5 mg carbadox/kg body weight/day (= maximum autho­
rized Level) to pigs the residues in edible tissues are less than 
5/i.g/kg (Limit of determination) six hours after withdrawal of 
the supplemented feedingstuff for carbadox, and 72 hours after 
withdrawal for desoxycarbadox. 
Twenty­four hours after withdrawal, residues consisting essentially 
of quinoxaline­2­carboxylic acid and small amounts of methylcarba­
zate are less than 0.1 mg/kg in all tissues except the liver, 
where they reach 1.0 mg/kg. Their concentration in this organ 
decreases progessively, being 0.1 mg/kg after two weeks and 
0.03 mg/kg (limit of determination) after four weeks. A four­week 
withdrawal period therefore suffices for elimination of the 
residues. 
Carbadox and its metabolites have been investigated in short­ and 
long­term toxicological studies in laboratory animals. Admini­
stration of carbadox for two years in the daily diet of rats pro­
duced toxic effects (nodular hepatoma) at doses above 2.5 mg/kg 
body weight. The compounds causing these effects have been shown 
to be carbadox and desoxycarbadox. The long­term administration 
of daily doses up to 50 mg/kg body weight of quinoxaline­2­carboxylic 
acid (main metabolite) or of 10 mg/kg body weight of methylcarbazate 
produced no adverse effects. 
The induction of a variety of mutagenic effects in certain strains 
of microorganisms, Drosophila and mice appeared to be associated 
with chemicals having a quinoxaline­N,Ν'­dioxide structure. This 
property has not been observed with the metabolic products of car­
badox and desoxycarbadox. 
These results show that residues of carbadox can be considered to 
be of low toxicity as soon as the original compound and desoxycar­
badox have disappeared, i.e. 72 hours after administration of the 
product. 
Carbadox residues produced no adverse effects in relay toxicity 
studies carried out during two years over three generations in 
rats, and for 87 months in dogs. The test animals were fed during 
these trials rations containing meat and/or Liver from pigs which 
had received 200 mg carbadox/kg feedingstuff (four times the 
maximum authorized Level) and had been slaughtered without any 
withdrawal period. In neither case were any harmful effects 
observed. 
2. Although carbadox has antibacterial properties, it modifies only 
slightly the intestinal flora of animals. It does not induce the 
selection of enterobacteriaceae (E. coli or others) carrying 
R-plasmids nor does it cause a transfer of R-factors. Despite 
continuous use for several years in pigs, a decrease of transferable 
resistance to chemotherapeutics was observed in E. coli of the 
intestinal flora. This more sensitive flora tended to become 
dominant. 
3. Carbadox with a chemical and physico-chemical specification con-
sidered satisfactory by the Committee is available commercially 
as a permix containing soya oil. This inert ingredient prevents 
the formation of dust during the preparation of the premix and 
the feedingstuff. Surveys conducted in factories indicate that 
these products may be handled safely. The risks to agricultural 
workers appear negligible if the feedingstuff is in pellet form. 
61-72 % of the dose ingested by pigs is excreted in the urine 
and 2-10 % in the faeces during the 24 hours following admini-
stration. The total quantity excreted after 72 hours amounts to 
85-90 '/.. The excreted products contain only traces of carbadox 
and desoxycarbadox.They consist essentially of quinoxaline-2-carboxy-
lic acid and methylcarbazate either in their free or conjugated 
forms. These compounds are neither toxic nor mutagenic. They 
are polar compounds which, on the basis of present knowledge, do 
not appear to accumulate in the food chain or to pollute the 
environment. 
4. In the light of the available data the Committee is of the opinion 
that the use of carbadox cannot lead to the presence of residues 
in animal products provided the conditions of use mentioned below 
are adhered to, nor that it is harmful to the environment or to 
persons required to handle the product in industry and/or agri-
culture. 
Conditions of use 
Feedingstuffs for pigs, up to the maximum age of four months. 
Maximum carbadox content : 50 mg/kg of complete feedingstuff. 
Presentation of the feedingstuff : pellets. 
Withdrawal period of the supplemented feedingstuff : at least 
four weeks before slaughter. 
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REPORT OF THE SCIENTIFIC COMMITTEE FOR ANIMAL NUTRITION ON THE USE 
OF HALOFUGINONE IN FEEDINGSTUFFS FOR CHICKEN 
Opinion expressed 25 April 1979 
TERMS OF REFERENCE 
The Scientific Committee for AnimaL Nutrition was requested to give 
an opinion on the following questions : 
1. Does the use of the coccidiostat halofuginone in feedingstuffs for 
chicken, under the conditions of use authorized by derogation (see 
Background), result in the presence of residues in animal products ? 
If so, what is the nature and the amount of these residues ? Could 
these residues be harmful to the consumer ? 
2. Could the excreted products, derived from the additive, be prejudicial 
to the environment ? If so, what is the nature of the risks ? 
3. In the light of the answers to the above questions, should the 
conditions of use already authorized for this additive be main-
tained or should they be modified ? 
BACKGROUND 
In accordance with the provisions of Council Directive 70/524/EEC, of 
23 November 1970, concerning additives in feedingstuffs (1), as last 
amended by the twentieth Commission Directive of 7 December 1977 (2), 
Member States are authorized to use halofuginone, by way of derogation 
up to 31 December 1978, under the following conditions set out in 
Annex II, Section B, of the Directive : 
Species of animal : Chicken for fattening. 
Minimum and maximum content in complete feedingstuffs : 2 - 3 ppm 
(mg/kg) 
Other provisions : use prohibited at least 5 days before slaughter. 
(1) OJ No L 270, 14.12.1970, p. 1 
(2) OJ No L 18, 24.01.1978, p. 7 
12 
OPINION OF THE COMMITTEE 
1. Studies of the metabolism of halofuginone (dl-trans-7-bromo-6-
chloro-/"3-(3-hydroxy-2-piperidyl)acetonyl7-4(3H)-quinazolinone 
hydrobromid) in chicken, using compounds with the 14C-label in-
corporated either in the piperidine or the quinazolinone nucleus, 
show that the product does not undergo intensive metabolic degra-
dation in animals. Residues in tissues and organs appear to consist 
mainly of halofuginone and non-polar metabolites containing the 
piperidine and quinazolinone nuclei. 
Residues in tissues and organs of chicken which had been fed for 
several weeks with a ration containing 3 mg halofuginone/kg 
feedingstuff (maximum authorized level) were determined by measure-
ment of total radioactivity and by high-pressure liquid chromato-
graphy. Residues were negligible (less than 0.03 mg/kg) in 
muscle, skin and fatty tissue 24 hours after withdrawal of the 
supplemented feedingstuff. Small amounts (less than 0.06 mg/kg) 
were still present in the liver and kidney 5 days after withdrawal. 
Halofuginone was investigated in short- and long-term toxicological 
studies in laboratory animals. The Committee considered that 
certain observed effects, one of which was an increase in the 
incidence of lymphoreticular tumours in mice, required further 
investigation. The interpretation of these effects is difficult 
because of the use of animal strains with a tendency for developing 
similar tumours spontaneously and because studies on mutagenesis, 
histopathology and clinical chemistry were limited. The acquisi-
tion of more extensive data on these aspects is essential because 
of the low acceptable daily intake of the product for mice, rats 
and dogs, and because the metabolites are incompletely known. 
2. Studies on the fate of halofuginone in chicken showed that, under 
the authorized conditions of use, about 80 % of the amount ingested 
appears in the excreta within the next 24 hours. Excretion con-
tinues for about a week. The presence of residues in bile indicates 
the existence of an enterohepatic cycle. The excreted products 
appear to be composed mainly of halofuginone and non-polar meta-
bolites of similar structure. 
Tests performed on different types of soil showed that these 
products are strongly adsorbed, difficult to extract with water 
and resistant to biodegradation. Halofuginone is not phytotoxic 
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in tests carried out on tomato, cucumber. Lettuce and tobacco crops. 
These observations indicate that contamination of the environment 
is unlikeLy. However, additional, data on biodegradation of excreted 
products and on their effects on soil microbiology and aquatic 
life are necessary in order to remove any uncertainties. 
In the light of the available facts, the Committee is of the opinion 
that the use of halofuginone in feedingstuffs for chicken, at the 
levels presently authorized, could be maintained provisionally, 
provided a withdrawal period of at least 7 days before slaughter 
is imposed in order to assure the elimination of residues from 
liver and kidneys. A reassessment of this additive is needed, after 
a more detailed study of the long-term toxicity in rats and addi-
tional studies on the biodegradation of the residues excreted by 
chicken as well as the possible effects on soil micro-organisms 
and aquatic life have been carried out. 
REFERENCES 
Dossiers Roussel Uclaf and Huntingdon Research Center. 
- 14 
REPORT OF THE SCIENTIFIC COMMITTEE FOR ANIMAL NUTRITION ON 
THE USE OF MONENSIN SODIUM AND FLAVOPHOSPHOLIPOL IN FEEDINGSTUFFS 
FOR FATTENING CATTLE 
Opinion expressed 26 April and 11 July 1979 
TERMS OF REFERENCE 
The Scientific Committee for Animal Nutrition was requested to give 
an opinion on the following questions : 
1. Does the use of the antibiotics monensin sodium and flavophospholipol 
in feedingstuffs for fattening cattle, under the conditions of 
use authorized by derogation (see Background), result in the 
presence of residues in animal products ? If so, what is the 
nature and the amount of these residues ? Could these be harmful 
to the consumer ? 
2. Could the excreted products, derived from these additives, be 
prejudicial to the environment ? If so, what is the nature of 
the risks ? 
3. In the light of the answers to the above .questions, should 
the conditions of use already authorized for these additives be 
maintained or should they be modified ? 
BACKGROUND 
In accordance with the provisions of Council Directive 70/524/EEC, 
of 23 November 1970, concerning additives in feedingstuffs (1), as 
last amended by the twenty-fourth Commission Directive of 28 July 
1978 (2), Member States are authorized to use flavophospholipol and 
monensin sodium by way of derogation up to 31 December 1978, under the 
following conditions set out in Annex II, Section A, of the Directive : 
(1) 0J No L 270, 14.12.1970, p. 1 
(2) OJ No L 247, 9.09.1978, p. 25 
Additif Species of 
animal 
ppm (mg/kg) of com-
plete feedingstuff 
Minimum 
content 
Maximum 
content 
Other provisions 
Flavophos-
pholipoL 
Monensin 
sodium 
Cattle for 
fattening 
Cattle for 
fattening 
10 
15 
40 
Maximum dose in the daily 
ration : 50 mg 
Maximum dose in the daily 
ration : 
- Cattle from the commence-
ment of rumination up to 
250 kg : 125 mg 
- Cattle of more than 250 
kg and up to 450 kg : 
250 mg 
- Cattle of more than 450 
kg : 360 mg 
In addition to the label-
ling provisions referred 
to in Article 10, give the 
following instruction: 
"Keep out of reach of 
equine species". 
A recent examination revealed a divergence between the maximum levels 
established respectively for the daily ration and the complete feeding-
stuff for flavophospholipol. Moreover/the relationship between the 
maximum doses of monensin sodium in the daily ration and the ranges 
of cattle body weight was not appropriate. 
Considering the normal dose-levels of these additives in the daily 
ration, it was proposed 
- to fix the minimum and maximum content for flavophospholipol in 
complete feedingstuffs at 2 and 5 mg/kg respectively, 
- to maintain the minimum and maximum content (10 and 40 mg/kg) for 
monensin sodium in complete feedingstuffs, 
- to delete for both products the provisions on maximum doses in the 
daily ration, because these additives are intended for supplemen-
tary feedingstuffs and because the conditions of use of these feeds 
are subject to the labelling provisions of Article 11 of the 
di recti ve. 
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OPINION OF THE COMMITTEE 
A. USE OF MONENSIN SODIUM 
Opinion expressed 26 April 1979 
1. Monensin is an antibiotic produced by Streptomyces cinnamonensis. 
The active ingredient of the marketed mycelian product is the 
sodium salt of monensin. 
Monensin sodium is not absorbed in appreciable quantities from 
the digestive tract when incorporated in feed for fattening cattle 
according to the authorized conditions of use. No residues were 
detected in tissues and organs by microbiological analysis (limit 
of determination : 0.05 mg/kg). Traces of the product appeared 
in the liver of cattle receiving daily doses of 750 mg of the 
product (i.e. more than three times the maximum authorized level) 
for 106 days up to slaughter. These residues disappear when the 
treatment is stopped 48 hours before slaughter. 
Investigations using 14C-labelled monensin sodium showed that, 
under normal conditions of use of the product (30-40 mg/kg of 
complete feedingstuff), residues were absent (limit of detection 
of radioactivity expressed as monensin sodium : 0.021 mg/kg) 
from the edible tissues and organs, except the liver. Residues 
in the liver varied with the animal from 0.21 to 0.59 mg/kg. 
Further investigation showed that these residues are comprised 
of 2-3 % of monensin sodium and a large number of metabolites 
resulting from demethylation, hydroxylation and/or decarboxylation 
of the product. The presence of monensin sodium and its metabo-
lites in concentrations of 13-14 mg/kg in the bile suggests that 
this is the active route of elimination. 
Monensin was investigated in short- and long-term toxicological 
studies, including carcinogenicity, mutagenicity, reproduction 
tests over several generations and tests on allergic effects. 
Short-term toxicological studies, relay toxicity in dogs and 
rats and tests on allergic effects were also performed on the 
mycelian product. No significant clinical, biochemical or histo-
pathological alterations nor any carcinogenic, teratogenic, 
mutagenic or allergenic effects were observed. 
The use of monensin sodium under the authorized conditions is 
therefore not prejudicial to the consumer. 
2. Monensin is eliminated in ruminants for the most part unchanged 
in the faeces, the rest being in the form of microbiologically 
inactive metabolites. The active principle then decays by 
30-40 % in faecal matter in 10 weeks, by more than 80 % in 
manure in 11 weeks and by more than 80 % in soil in two weeks. 
Phytotoxicity studies were carried out on plants in the germi-
native and vegetative stages. Field trials were performed in 
soils fertilized with manure from cattle which had been fed 
rations containing monensin sodium. No phytotoxic effects were 
observed. Investigations on soil micro-organisms, including 
nitrogen fixers, did not show any interference by the product. 
In the light of these data and because of the low solubility of 
monensin sodium in water, there is no reason to suspect a conta-
mination of the environment under the authorized conditions of use. 
3. After consideration of all available documentation, the Committee 
considers that the dose-levels authorized, i.e. 10-40 mg/kg of 
complete feedingstuff, should be maintained together with the 
instruction "keep out of reach of equine species". 
In order to prevent incorrect use of monensin sodium in ruminant 
cattle receiving supplementary feedingstuffs, it is considered 
useful to establish a maximum daily dose per animal based on live 
weight. It is accepted that feed intake of ruminant cattle does 
not increase in direct proportion to body weight. This necessi-
tates an adjustment of the amount of additive in the ration. 
In view of the foregoing, the Committee is of the opinion that 
the maximum amount of monensin sodium in the daily ration should 
not exceed : 80 mg (constant value) + 60 mg/100 kg live weight. 
The values obtained according to this formula are as follows : 
Weight of 
the ani-
mal (kg) 
100 
150 
200 
250 
300 
350 
400 
450 
500 
550 
600 
Average daily 
consumption 
of feed (kg) 
3.4 
4.4 
5.6 
6.7 
7.6 
8.3 
9.0 
9.6 
10.4 
10.5 
10.9 
mg monensin sodium/heac 
/day (80 mg + 60 mg/100 
kg live weight) 
140 
170 
200 
230 
260 
290 
320 
350 
380 
410 
440 
ppm equivalent (mg 
monensin sodium/kg 
complete feeding-
stuff) 
41 
39 
36 
34 
34 
35 
36 
36 
37 
39 
40 
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The Committee therefore proposes to replace the maximum doses, at 
present Laid down for the daiLy ration, by the following provision 
"For ruminant cattle receiving supplementary feedingstuffs, the 
maximum dose in the daily ration shall be adjusted so as not to 
exceed 80 mg + 60 mg/100 kg live weight". 
REFERENCES 
Dossiers Lilly Research Centre Ltd. 
Burrel W.C., Wiltbank J.N. and Veenhuisen E., 1977. Proc. Ann. Meet. 
Am. Soc. Anim. Sci., Western Section 28, 191-194 
Chen Nin and Wolin M.J., 1979. Appi. Env. Microbiol. 38, 72-77 
Chew B.P., Randel R.D., Rouquette F.M. Jr. and Erb R.E., 1978. J. 
Anim. Sci. 46. (5), 1316-1325 
Donoho Α., Manthey J., Occolowitz J. and Zornes L., 1978. 
J. Agrie. Food Chem. 26_ (5), 1091-1095 
Haney M.E. and Hoehn M.M., 1967. Antimicrobial Agents and Chemotherapy 
349-352 
Herberg R., Manthey J., Richardson L., Cooley C. and Donoho Α., 1978. 
J. Agrie. Food Chem. 26 (5), 1087-1090 
Van Maanen R.W., Herbein J.H., McGilliard A.D. and Young J.W., 1978. 
J. Nutrition 108 (6), 994-1001; 1002-1007 
Wade Steen W., Gay N., Boling J.Α., Bradley N.W., Mc Cormick J.W. and 
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Β. USE OF FLAVOPHOSPHOLIPOL 
Opinion expressed 11 July 1979 
1. Flavophospholipol is an antibiotic produced by Streptomyces 
bambergiensis. The marketed product is myceLian. 
FLavophospholipol is not absorbed in appreciable quantities from 
the digestive tract when incorporated in feed for fattening cattle 
according to the conditions of use authorized. No residues were 
detected in the tissues and organs by microbiological analysis (*). 
Flavophospholipol residues up to 1 mg/kg were found in the liver 
of cattle receiving 600 mg of the product daily for 140 days up 
to slaughter. No residues were found under the same experimental 
conditions with a dosage of 400 mg. 
Balance studies and investigations using 32P­labelled flavophos­
pholipol showed that orally administered, the product is elimi­
nated unchanged in the faeces without any metabolites being formed. 
The stability of the product is explaned by its resistance to the 
action of various enzymes. 
Short­ and long­term toxicity studies were carried out on both 
the pure substance and the mycelian product. No significant 
clinical, biochemical or histopathological changes were observed 
nor any carcinogenic, teratogenic, mutagenic or allergenic effects. 
Pharmacological investigation of the mycelian product did not 
reveal any stimulant or depressing effect on the central nervous 
system nor any muscle­relaxing, analgesic, spasmolytic, pressor, 
gonadotroph!c, glycaemic or neurotoxic effects. Flavophospholipol 
produced no clinical symptoms when administered to human volunteers. 
The use of flavophospholipol under the authorized conditions is 
therefore not prejudicial to the consumer. 
2. Practically 100 % of the flavophospholipol contained in the ration 
of ruminants is eliminated unchanged in the faeces. The anti­
biotic activity of the compound reaching the soil with manure 
decreases steadily and in 5­6 weeks declines to 15 %. The decay 
of the antibiotic activity declines to 15 % after 7 days in the 
faeces of cattle which have been receiving feed supplemented with 
flavophospholipol for a long period. Flavophospholipol present 
in the soil is not absorbed by vegetation. 
In the light of these data and because of the low solubility of 
flavophospholipol in water there is no reason to suspect a conta­
mination of the environment under the authorized conditions of use. 
(*) Limit of determination : 
Muscular tissue and organs : 0.2 ­ 0.5 mg/kg 
Adipose tissue : 0.2 ­ 0.4 mg/kg 
Blood : 0.1 mg/l 
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3. After consideration of aLL available documentation, particularly 
on the efficacy of the product, the Committee considers that the 
dose-levels authorized should be limited to 2-10 mg/kg of complete 
feedingstuff. 
In order to prevent incorrect use of flavophospholipol in ruminant 
cattle receiving supplementary feedingstuffs, it is considered 
useful to establish a maximum daily dose per animal based on live 
weight. It is accepted that feed intake of ruminant cattle does 
not increase in direct proportion to body weight. This necessitates 
an adjustment of the amount of additive in the ration. 
In view of the foregoing, the Committee is of the opinion that the 
maximum amount of flavophospholipol in the daily ration should 
not exceed : 25 mg (constant value) + 15 mg/100 kg live weight. 
The values obtained according to this formula are as follows : 
Weight of 
the ani-
mal (kg) 
100 
150 
200 
250 
300 
350 
400 
450 
500 
550 
600 
Average dai ly 
consumption of 
feed (kg) 
3.4 
4.4 
5.6 
6.7 
7.6 
8.3 
9.0 
9.6 
10.4 
10.5 
10.9 
mg flavophospholipol/ 
head/day (25 mg + 15mg/ 
100 kg live weight) 
40 
47.5 
55 
62.5 
70 
77.5 
85 
92.5 
100 
107.5 
115 
ppm equivalent (mg 
flavophospholipol/kg 
complete feeding-
stuff) 
11.7 
10.8 
9.8 
9.3 
9.2 
9.3 
9.4 
9.6 
9.6 
10.2 
10.5 
The Committee therefore proposes to replace the maximum doses, at 
present laid down for the daily ration, by the following provision 
"For ruminant cattle receiving supplementary feedingstuffs, the 
maximum dose in the daily ration shall be adjusted so as not to 
exceed 25 mg + 15 mg/100 kg live weight." 
-Ci. 
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REPORT OF THE SCIENTIFIC COMMITTEE FOR ANIMAL NUTRITION ON 
THE USE OF AVOPARCIN IN FEEDINGSTUFFS FOR CHICKEN AND PIGS 
Opinion expressed 11 July 1979 
TERMS OF REFERENCE 
The Scientific Committee for Animal Nutrition was requested to give 
an opinion on the following questions : 
1. Does the use of the antibiotic avoparcin in feedingstuffs for 
chicken and pigs, under the conditions of use authorized by dero-
gation (see Background), result in the presence of residues in 
animal products ? If so, what is the nature and the amount of 
these residues ? Could these residues be harmful to the consumer ? 
2. Could the use of this additive affect the development of resistance 
in bacteria ? 
3. Could the excreted products, derived from the additive, be pre-
judicial to the environment ? If so, what is the nature of the 
risks ? 
4. In the light of the answers to the above questions, should the 
conditions of use already authorized for this additive be main-
tained or should they be modified ? 
BACKGROUND 
In accordance with the provisions of Council Directive 70/524/EEC, 
of 23 November 1970, concerning additives in feedingstuffs (1), as 
last amended by the twentieth Commission Directive of 7 December 1977 
(2), Member States are authorized to use avoparcin, by way of dero-
gation up to 31 December 1978, under the following conditions set 
out in Annex II, Section A, of the Directive : 
Species of animal 
Chicken for fattening 
Pigs, up to 10 weeks 
Pigs, more than 10 weeks 
Minimum 
content 
Maximum 
content 
ppm (mg/kg) of complete feedingstuffs 
7.5 
10 
5 
15 
40 
20 
(1) OJ No L 270, 14.12.1970, p. 1 
(2) 0J No L 18, 24.01.1978, p. 7 
OPINION OF THE COMMITTEE 
1. Avoparcin is a gLycopeptide antibiotic produced by Streptomyces 
candi dus. The active substance of the myceLian product on the 
market is avoparcin lauryl sulphate. 
Radiotracer methodology sensitive to 0.05 mg/kg has been used 
to follow the routes and rates of excretion and the distribution 
in tissues of HC-labelled avoparcin administered to rats and to 
broiler chicken. The radioactivity was quantitatively recovered 
in the excreta after a few days and there were no measurable 
residues in muscle, fat, liver and kidneys. 
Investigations on residues in tissues were also carried out in 
a number of experiments with chicken and pigs receiving avoparcin 
in their ration according to the conditions of use authorized 
and also at higher levels. There were no microbiologically de-
tectable residues (limit of detection : 0.2 to 0.5 mg/kg, according 
to the substrate) nor any antibiotic activity in the muscle, 
fat, blood, liver, kidneys and skin at slaughter after withdrawal 
periods of 0, 1 and 3 days. The investigation of the muscle and 
liver by a gas-chromatographic method confirmed the absence of 
residues at the detection limit of 0.1 mg/kg. 
Avoparcin has been investigated in short- and long-term toxicity 
studies in laboratory animals. It had a low acute toxicity 
(oral LD50 for rat, mouse and chick exceeds 10 g/kg body weight). 
Long-term studies in rats fed diets containing various doses of 
the mycelian product did not show any significant dose-related 
differences from the control groups in the usual parameters nor 
was there any indication that avoparcin induces specific tumours. 
A three-generation study in rats showed decreased neonatal sur-
vival and lower body weights of the young only at the highest 
dose investigated (1600 mg avoparcin/kg feedingstuff). No abnor-
malities were observed in relay toxicity studies in rats fed for 
90 days a diet containing 33 % of tissues from chicken reared 
for nine weeks on feed containing 500 mg avoparcin/kg. 
2. Avoparcin is active in in vitro tests against gram-positive but 
not gram-negative bacteria and has been shown to have no signi-
ficant influence on the flora of the small intestine of broiler 
chicken. Despite a slight development of resistance in vitro 
in strains of enterococci, there is no evidence that the use of 
avoparcin in the diet of pigs and chicken favours the selection 
of bacteria with stable resistance in Clostridium welchii, group 
D streptococci and nasal staphylococci. The development of 
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cross­resistance between avoparcin and a number of therapeutic 
antibiotics has been studied in pigs. There was no evidence 
that avoparcin, at LeveLs of 20 to 200 ppm in the diet, induced 
the selection of bacteria resistant to avoparcin itself, or to 
any of the other therapeutic antibiotics tested. 
3. The elimination of avoparcin lauryl sulphate in pig and chicken 
excreta and the stability of the excretion products in manure 
have been studied. The additive passes through the digestive tract 
of pigs mostly undegrated, but in chicken only about half of the 
antibiotic activity of the ingested dose appears in the excreta. 
Antibiotic activity appears to decline more rapidly in chicken 
excreta than in pig faeces. After storage at 24°C and 37°C the 
half life values of avoparcin (based on antibiotic activity) were 
respectively 9 and 4 days in chicken excreta and 22 and 15 days 
in pig faeces. 
Avoparcin breakdown products are strongly bound in the soil. 
Hence only very small amounts of the antibiotic and its residues 
are likely to enter the aquatic environment either by drainage 
or directly. The results of a study in an ecosystem model and 
a study of the bioaccumulation potential suggest that manuring 
with chicken excreta containing avoparcin will not result in the 
accumulation of avoparcin or related residues in components of 
the environment, only trace amounts being taken up by plants 
and animals. Avoparcin has no obvious phytotoxic effect on crop 
plants and weed species and is of low toxicity to aquatic orga­
nisms . 
4. The Committee considered all available information, particularly 
the data showing that avoparcin has a low toxicity for mammals 
and aquatic life, that it is virtually not absorbed from the 
gastro­intestinal tract, and the absence of any evidence that 
its use in feedingstuffs could lead to the development of resis­
tant or cross­resistant bacteria and thereby diminish the effec­
tiveness of therapeutically used antibiotics. In the Light of 
the above information, the Committee is of the opinion that the 
use of avoparcin in chicken for fattening, piglets and pigs, 
under the authorized conditions, is not prejudicial to the con­
sumer nor to the environment and should be maintained. 
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GUIDELINES FOR THE ASSESSMENT 
OF ADDITIVES IN FEEDINGSTUFFS 
GENERAL ASPECTS 
This document is intended as a guide for establishing dossiers on 
substances being submitted for authorization as additives in feeding-
stuffs. These dossiers should enable an assessment of the additives 
based on present state of knowledge and should ensure their compliance 
with the fundamental principles laid down for their admission, which 
are the subject of the provisions of Article 6(2) of Council Direc-
tive 70/524/EEC, of 23 November 1970, on additives in feedingstuffs (*). 
For this purpose all the studies outlined in this document and schema-
tized below (cf. Presentation of studies), may be required and, if 
necessary, additional information may be requested. However, no 
study which is obviously superfluous or inappropriate for an additive 
will be required. 
As a general rule, all the information to establish the identity, 
physico-chemical properties, presentation, conditions of use, methods 
of determination and effectiveness of the additive, its balance, 
tolerance, biological and toxicological effects on target species must 
be provided, together with data on the effects on human health and 
the environment, which may result directly or indirectly from its use. 
The studies necessary for the evaluation of risks will depend essen-
tially on the nature of the product and the circumstances of its use. 
In this respect, no strict rule is applicable. It is understood that 
additives intended exclusively for pet foods will not be subject to 
the same requirements as additives intended for feedingstuffs for 
productive livestock whose products are consumed by man or whose 
excrements could constitute a significant source of pollution for the 
environment. 
A knowledge of the metabolism and fate of the additive in productive 
livestock is essential. In particular it will permit the determination 
of the extent of pharmacological and toxicological studies to be 
performed on laboratory animals in order to assess the risks for the 
consumer. However, this evaluation cannot be based solely on studies 
confined to determining the direct effects of the additives on labo-
ratory animals. The latter do not provide specific information on 
the toxicity and bioavailability of residues resulting from the meta-
bolism in the species for which the additive is intended. 
These guidelines are applicable generally but require that the necessary 
documentation be adapted to each case. This documentation should 
include detailed reports, presented in the order and with the numbering 
proposed in these guidelines,and should be accompanied by a summary. 
The omission of any studies proposed in these guidelines should be 
justified. The publications quoted as references should be attached. 
(*) 0J No L 270, 14.12.1970, p. 1 
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OBSERVATIONS 
The term "additive", as used in this document, refers to the active 
substances in the state in which they wiLL be incorporated in premixes 
and feedingstuffs. The evaluation of these additives will also take 
into consideration the preparations to be used in feedingstuffs and 
the possible use of the relevant active substances in human nutri­
tion and human and veterinary therapy. 
The guidelines will be up­dated as new scientific knowledge develops. 
PRESENTATION OF STUDIES 
I. Identity, physico­chemical properties, presentation and conditions 
of use, methods of determination of the additive. 
II. Studies concerning the effectiveness of the additive for the 
intended use. 
III.Studies concerning the biological consequences of the use of the 
additive in feedingstuffs (for productive livestock, cf. scheme 
below). 
IV. Other relevant studies. 
Study scheme (*) 
Productive livestock 
(additive included in feed) 
i 
Study of the 
tolerance, biolo­
gical and anatomo­
pathological effects. 
Effects on intestinal 
flora, study of 
bacterial resis­
tance, etc. 
Balance studies 
Not absorbed 
­via enterohe­
patic system t 
Additive and/or metabo­
lites eliminated Φ 
via kidneys 
Absorbed 
I 
Metabolism 
Residues 
(active substance, 
impurities, meta­
bolites) in animal 
tissues and pro­
ducts 
Faeces Urine 
1 I 
Excreted products 
deriving from the additive 1 i 
Environmental effect 
Subchronic and 
chronic toxicity 
studies on labora­
tory animals 
(*) Application of all or part of the scheme may be required, depending on 
the nature of the additive and the circumstances of its use. 
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SECTION I : IDENTITY, PHYSICO-CHEMICAL PROPERTIES, PRESENTATION AND 
CONDITIONS OF USE, METHODS OF DETERMINATION OF THE ADDITIVE, 
1 . IDENTITY 
1.1. Chemical name of the additive, existing synonyms and abbrevia-
tions; 
1.2. Molecular and structural formulae. If the active substance 
cannot be chemically defined or is a fermentation product, 
indicate empirical formula; 
1.3. Degree of purity of the additive. Qualitative and quantitative 
data on any impurities present; 
1.4. Manufacturing and purification processes, consistency of com-
position of the product in the course of production, methods 
used to check the consistency. 
N.B. If the active substance is a mixture of two or more compounds, 
describe each compound separately and give their proportion in 
the mixture. 
2. PHYSICO-CHEMICAL PROPERTIES 
2.1. Physical properties of the additive (physical state, particle 
size, electrostatic properties, melting point, boiling point, 
decomposition temperature, density, vapour pressure, solubility 
in various solvents, UV and IR spectra, etc.); 
2.2. Stability of the additive on exposure to atmospheric agents 
(light, temperature, moisture, etc.); 
2.3. Stability of the additive in premixes and feedingstuffs during 
manufacture and storage. Incompatabilities with other compo-
nents and possible decomposition products. Ability to obtain 
homogeneous mixtures at the proposed levels of incorporation 
in feedingstuffs. 
3. PRESENTATION AND CONDITIONS OF USE 
3.1. Proposed trade names for marketing the additive; 
3.2. Proposed preparation for marketing the additive. Qualitative 
and quantitative composition of the premixes and their content 
of additive; 
3.3. Intended use of the product in animal feed; 
3.4. Proposed concentrations of the additive in feedingstuffs; 
3.5. Other uses of the active substance in foodstuffs, human and 
veterinary therapy and the dosages to be applied. In each 
case list the tradenames and indications for these uses. 
4. METHODS OF DETERMINATION 
4.1. Methods of analysis to determine the degree of purity of 
the additive, the nature and amount of impurities; 
4.2. Qualitative and quantitative methods for the determination of 
the additive in premixes and feedingstuffs; 
4.3. Qualitative and quantitative methods of analysis used to 
establish the balance sheet and the metabolism of the additive 
in livestock and its fate in the environment (determination 
of the active substance, its impurities and metabolites in 
organs and tissues, eggs, milk etc; determination of the 
nature of the excreted products, derived from the additive, 
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in excreta, manure, soiL and water); 
4.4. Qualitative and quantitative methods for the determination 
of residues in food (these methods should be specific and 
sensitive). 
N.B. All the methods specified should be accompanied by information 
as to percentage recovery, specificity, sensitivity, possible 
interferences by other additives, limits of detection, margin 
of error. Reference standards of the additive, of the pure active 
substance and, if possible, of the main metabolites should be 
available. 
SECTION II : STUDIES CONCERNING THE EFFECTIVENESS OF THE ADDITIVE 
FOR THE INTENDED USE 
1. TECHNOLOGICAL AND ANIMAL PERFORMANCE STUDIES 
1.1. Evidence of the effectiveness of the additive under the 
intended conditions of use 
1.1.1. in technology, in comparison with reference feedingstuffs 
and, possibly, feedingstuffs containing additives of known 
effectiveness; 
1.1.2. in animal production, in comparison with animals in control 
groups, and possibly, animals in groups receiving feeding-
stuffs containing additives of known effectiveness (effect 
on growth rate, feed conversion rate, morbidity, mortality, 
etc.). 
1.2. Effect of the additive on nutritive, technological and orga-
noleptic quality of carcasses, meat, offal, eggs, milk, etc. 
2- EXPERIMENTAL CONDITIONS IN THE STUDIES ON ANIMAL PERFORMANCE 
Give a detailed description of the tests performed and 
provide the following data : 
2.1. Species, breed, age and sex of the animals, identification 
procedure; 
2.2. Number of test and control groups; number of animals in each 
group (the number should be large enough for statistical 
analysis using suitable statistica., parameters); 
2.3. Dose-levels of the additive, percentage of the ingredients 
of the ration and detailed analysis thereof; 
2.4. Location of each experiment, physiological and animal health 
conditions, rearing conditions (these should reflect those 
used in practice in the Community); 
2.5. Date and exact duration of testing, date of examinations 
performed; 
2.6. Adverse effects which occurred during the experiment and time 
of their appearance. 
SECTION III : STUDIES CONCERNING THE BIOLOGICAL CONSEQUENCES OF THE 
USE OF THE ADDITIVE IN FEEDINGSTUFFS 
The studies outlined in this section are intended to permit assessment 
of the safety in use of the additive in all the target species, and 
of the risks for man and the environment which could result directly 
or indirectly from this use. The data required may vary with the 
nature of the additive and the animal species concerned. A knowledge 
of the balance and fate of the additive will always be essential for 
determining the need for and the extent of the information required. 
As a general rule, all the additives intended for feedingstuffs for 
productive livestock should be investigated to determine the nature 
of the excreted products, the fate of these products in manures, 
slurries, soils and water, and their effects on soil biology and 
aquatic life. For additives intended for feedingstuffs for live-
stock whose products are consumed by man, detailed studies are re-
quired on their metabolism (as indicated in the scheme outlined 
under "Presentation of studies") and on the residues in animal pro-
ducts (composition, persistence, pharmacological effects, subchronic 
and chronic toxic effects) in all cases where the balance studies 
indicate intestinal absorption. These studies should be performed 
on all animal species concerned under the practical conditions of 
use proposed for each additive. 
1. STUDIES ON TARGET SPECIES 
1.1. Study of the tolerance of the additive and of its biological, 
toxicological and anatomo-pathological effects. Determination 
of the safety coefficient (margin between the proposed maximum 
dose-level and that resulting in adverse effects); 
1.2. Study of the balance of the additive (level of absorption, 
level of elimination in faeces, urine, etc.); 
1.3. Study of the metabolism and pharmacokinetics of the additive 
(fate in the organism, absorption, distribution and elimi-
nation, etc.); 
1.4. Study of the effects of the additive on microorganisms, in 
particular the microorganisms of the intestinal flora, and 
of the phenomena of bacterial resistance relating to the 
selection of bacteria with induced chromosomal parallel re-
sistance to chemotherapeutics and R-plasmid carrying bacteria. 
Study of the effect of the additive on the colonization of 
pathogens in the intestinal tract. 
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2 . STUDY OF THE RESIDUES IN ANIMAL PRODUCTS 
2.1. Nature and concentration of the residues (active substance, 
impurities, metabolites) in tissues and organs, particuLarly 
in edible products (muscle, skin, liver, milk, eggs, etc.) 
after withdrawal of the supplemented feedingstuff; 
2.2. Persistence, half-life value and kinetics of elimination of 
these residues. In some cases, studies on the effects of 
storage and cooking may be required. 
3. STUDY OF EXCRETED PRODUCTS DERIVED FROM THE ADDITIVE 
3.1. Nature and concentration of the excreted products, derived 
from the additive (active substance, metabolites), in urine 
and faeces; 
3.2. Persistence, half-life value and kinetics of elimination of 
these products in manure, slurry, soil and water; 
3.3. Their effects on soil biology, in particular on nitrifying 
bacteria, on plant growth and aquatic life; 
3.4. Their effects on methane production. 
4. PHARMACOLOGICAL AND T0XIC0L0GICAL STUDIES ON LABORATORY 
ANIMALS 
These studies may be carried out on the additive, on its 
residues and derivatives of these residues in edible animal 
products, which are likely to be toxicologically significant. 
As far as possible, attempts should be made to select labo-
ratory animals showing metabolic similarities to the target 
species for which the additive is intended. 
The test substance should be administered daily and conti-
nuously in the diet in all oral subchronic and chronic tests. 
4.1. Acute toxicity 
Acute toxicity studies should be carried out in at least two 
animal species, one of which being a rodent (preferably the 
rat). The test substance should be administered orally, 
at several dose-levels, preferably in logarithmic progression, 
in order to establish the LD 50. Detailed observations 
should be given of the biological effects during a period 
up to two weeks after ingestion. 
4.2. Mutagenicity tests 
Investigations of potential mutagenicity, including in vitro 
screening tests using metabolic activation systems may 
contribute to the evaluation of the toxicity. 
4.3. Pharmacological studies 
Appropriate investigations should be made to reveal any 
pharmacological activities. 
4.4. Subchronic toxicity (at Least 90 days) 
In general, these studies should be carried out on two animal 
species, one of which being a rodent. The test substance 
should be administered orally at a minimum of three dose-
levels. These should be chosen so as to determine a no-
effect level and also a level permitting the establishment 
of a dose-response relationship. The experimental groups 
should contain an adequate number of animals of each sex. 
A control group should always be included. 
In certain cases, investigations extending over six months 
to two years in dogs or other non-rodents may be desirable 
to establish the variation in sensitivity of different animal 
species to the test substance. 
All relevant biological data should be recorded at appropriate 
intervals, particularly data on growth rate, feed consumption, 
haematology, urine analysis, biochemical parameters, mortality, 
organ weights, gross pathology and histopathology of major 
organs and tissues. If there is any evidence of specific 
toxic effects, these should be investigated to elucidate 
their origin and mechanism. 
The results should be presented in detail and, as far as 
possible, should include statistical assessment. 
4.5. Chronic toxicity 
In general, chronic toxicity studies should be carried 
out on two species of rodents. The substance should be 
administered orally in at least three dose-levels. Experiments 
should extend for a minimum of two years in the rat and 80 
weeks in mice. The experimental groups should contain an 
adequate number of animals of each sex. A control group 
should always be included. The experiment, if continued 
beyond the minimum period, should be terminated when survival 
in any but the highest dose-level group has fallen to 20 %. 
The biological examinations mentioned above (cf. item 4.4) 
should be carried out at appropriate intervals throughout 
the experiment and on the surviving animals at the end of the 
experiment. For assessing carcinogenicity, particular atten-
tion should be paid to the time of appearance, the histolo-
gical types of any observed tumours and their incidence. In 
certain cases, it may be necessary to investigate the possi-
bility of transplacental carcinogenicity. 
Reproduction studies should extend over at least two filial 
generations and may be combined with embryotoxicity including 
teratogenicity studies. Particular attention should be paid 
to fertility, fecundity and observation on post-natal develop-
ment of litters. 
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The results should be presented in detail and, as far as 
possible, should include statistical assessment. 
4.6. Relay toxicity 
In certain circumstances - in particular, where it is not 
possible to isolate or identify the metabolites of the 
additive, or in order to obtain indications on the bio-
availability of the residues - a relay toxicity study of 
at least 90 days may be desirable in addition to the studies 
required as indicated under items 4.1 to 4.5. 
In this test, rats or other laboratory animals should be fed 
the edible products of target species which have received 
the additive in their ration. The experimental animals should 
then be examined as indicated in 4.4 and 4.5. 
N.B. Any further toxicity study providing additional information use-
ful for the assessment of the test substance should be made 
available. 
4.7. Experimental conditions 
For all pharmacological and toxicological studies give a 
detailed description of the tests performed and provide the 
following data : 
4.7.1. Species, breed, strain and sex of animals; 
4.7.2. Number of test and control groups; number of animals in each 
group (the number should be large enough for statistical 
analysis using suitable statistical parameters); 
4.7.3. Dose-levels of the test substance, percentage of the ingre-
dients of the ration and detailed analysis thereof; 
4.7.4. General rearing conditions throughout the period of testing; 
4.7.5. Date and exact duration of testing; date of examinations 
performed; 
4.7.6. Rate and timing of deaths for the various lots; 
4.7.7. Pathological incidents which occured during the experiment 
and time of their appearance. 
SECTION IV : OTHER RELEVANT STUDIES 
Depending on the nature and the conditions of use of the additive, 
data on allergic effects, on irritation of the skin and mucous 
membranes of the eye, respiratory or digestive tract, and also tests 
on inhalation and percutaneous toxicity, using single and repeated 
doses, may be required to assess possible risks in handling premixes 
or supplemented feedingstuffs. If necessary the preventive measures 
and the means of protection to be applied should be indicated. 
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